Course outcome
V PHARM. D
CLINICAL PHARMACOKINETICS AND PHARMACOTHERAPEUTIC DRUG MONITORING (THEORY)
After a successful completion of the course the students will be able to
| Course outcome number | Course Outcomes | Cognitive level |
| CO1 | Students will be able to accurately describe and explain the foundational concepts of clinical pharmacokinetics, including the impact of various factors like age, weight, and disease on drug metabolism and the significance of pharmacokinetic drug interactions. | C1 |
| CO2 | Students will demonstrate the ability to apply pharmacokinetic principles to design optimal dosage regimens for diverse patient populations, considering various factors like renal and hepatic functions, and integrate knowledge to adapt dosages for patients with specific needs, such as the elderly, pediatrics, and obese patients. | C2 |
| CO3 | Students will develop the capability to critically analyze and evaluate the therapeutic drug monitoring (TDM) protocols and pharmacokinetic/pharmacodynamic correlations in drug therapy for managing diverse disease conditions like cardiovascular disease, seizure disorders, psychiatric conditions, and organ transplantations. | C3 |
| CO4 | By synthesizing knowledge from different modules, students will be adept at creating individualized, adaptive, and effective drug dosage regimens based on Bayesian theory and population pharmacokinetic data, adjusting for variability due to genetic, age, weight, and interacting drugs. | C4 |
| CO5 | Students will acquire proficiency in practically applying the learned principles to adjust dosages in cases of renal and hepatic diseases, taking into account extracorporeal removal of drugs and alterations in pharmacokinetics due to hepatic diseases. | C5 |
| CO6 | Learners will be able to comprehend the implications of genetic polymorphism in drug metabolism, transport, and targets, and will integrate pharmacogenetic considerations into pharmacokinetic and pharmacodynamic assessments to optimize therapeutic outcomes. | C6 |
